02/01/2007

Siemens AG Medical Solutions

Siemens expands its breast cancer care portfolio

New table introduced for biopsies after mammography

Siemens Medical Solutions recently began introducing its new MammoTest biopsy table for biopsies in the prone position during breast cancer screening. Together with the syngo Opdima biopsy unit, where the patient is in a sitting position, Siemens offers now a comprehensive biopsy portfolio with MammoTest. This provides the physician with the choice of two stereotactic systems. The ergonomically designed table ensures examinations as comfortable as possible for the patient.

Siemens acquired the rights to the MammoTest system last summer from Fischer Imaging. The technology enables 360 degree access to lesions. In addition, biopsies can be performed more accurately using Polar Coordinate Targeting and a high resolution CCD (charged coupled device) camera. This improves workflow while reducing the examination time.

Syngo Opdima is already the gold standard of digital biopsy and detailed imaging. It is designed for fast, efficient needle and core biopsies and for localization. With a detector resolution of 20 Lp/mm (line pairs per millimeter), syngo Opdima exceeds all comparable systems. The system is compatible with most of the mammography products of the Siemens Mammomat range, including the Mammomat Novation digital full field system.

“Siemens can now offer maximum flexibility in its biopsy solutions,” said Jochen Dick, head of the Special Systems product group at Siemens Medical Solutions. “With this new technology, we can now offer physicians a solution that best fits their needs – either the syngo Opdima system or the MammoTest as a table system for the prone position.”

Siemens Medical Solutions of Siemens AG(NYSE: SI) is one of the world’s largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics – such as Diagnostic Products Corporation and Bayer Diagnostics – mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (Sept. 30). Further information can be found by visiting http://www.siemens.com/medical